Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 27 full-time employees. The company went IPO on 2018-03-28. The company focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). The company has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Follow-Up Questions
Qui est le CEO de Q32 Bio Inc ?
Ms. Jodie Morrison est le Chief Executive Officer de Q32 Bio Inc, il a rejoint l'entreprise depuis 2024.
Quelle est la performance du prix de l'action QTTB ?
Le prix actuel de QTTB est de $1.84, il a decreased de 0.27% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Q32 Bio Inc ?
Q32 Bio Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Q32 Bio Inc ?
La capitalisation boursière actuelle de Q32 Bio Inc est de $22.5M
Est-ce que Q32 Bio Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour Q32 Bio Inc, y compris 3 achat fort, 3 achat, 4 maintien, 0 vente et 3 vente forte
